Effects of hypoxia on the mRNA expressions of TRAIL-mediated cell death related genes in hypoxia-tolerant rodent (Nannospalax nehringi) and some characteristics of these proteins
DOI:
https://doi.org/10.2298/ABS201119053YKeywords:
apoptosis, Nannospalax nehringi, hypoxia, TNF-related apoptosis-inducing ligand (TRAIL), inhibitors of apoptosis (IAPs), FLICE-like inhibitory protein (FLIP)Abstract
Paper description:
- TRAIL is a promising anti-cancer agent. Hypoxia is believed to effect TRAIL-mediated cell death (TMCD). Blind mole rats (BMRs) are hypoxia-tolerant rodents and have unique evolutionary characteristics against cancer and hypoxia.
- Effects of hypoxia on mRNA expressions of TMCD-related genes were detected; six protein sequences in Nannospalax nehringi genes were examined.
- These genes were regulated differently in the brain compared to the lungs. In addition, many mutations and insertions were found on the conserved regions of the genes.
- BMRs can contribute to the investigation of the effects of hypoxia on TMCD.
Abstract: The aim of the present study was to determine the mRNA expression profiles of TRAIL-mediated cell death related genes of the hypoxia-tolerant rodent Nannospalax nehringi under hypoxia. The nucleotide and amino acid sequences of these genes were identified. Captured Nannospalax nehringi were randomly divided into normoxia and hypoxia groups. The hypoxia group was exposed to a 7% O2 + 93% N2 gas mixture for 52 h, while animals in the normoxia group were housed under normoxic conditions. Total RNAs were isolated from brain and lung tissues. The cIAP-1, cIAP-2, XIAP, DcR1, DcR2, FLIP and OPG genes were PCR amplified, and the cIAP-1, cIAP-2, XIAP, OPG, TRAIL and FLIP genes were sequenced. Sequenced genes were translated into amino acid sequences and compared with reliable sequences of closely similar species. The genes in the brain were regulated for protection against hypoxia; however, the genes in the lung were regulated differently. Many mutations and insertions were observed on the conserved regions of the cIAP-1, cIAP-2, XIAP, OPG and TRAIL genes in N. nehringi. We propose that these gene mutations and insertions contribute to the anti-hypoxic properties of N. nehringi.
Downloads
References
Gordeeva AV, Labas YA, Zvyagilskaya RA. Apoptosis in Unicellular Organisms: Mechanisms and Evolution. Biochem Mosc. 2004;69(10):1055‑66.
Willms A, Schittek H, Rahn S, Sosna J. Mert U, Adam D. Trauzold, A. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. PloS One. 2019;14(4):e0214847.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157-63.
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420-30.
Westphal D, Dewson G, Czabotar PE, Kluck RM. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta BBA-Mol Cell Res. 2011;1813(4):521-31.
Spierings, DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004;52(6):821-31.
Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem. 2001;276(29):27322-8.
Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther. 2007;14(12):976-84.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99(11):4079-86.
Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol. 2008;76(12):1694-704.
Harris AL. Hypoxia - A Key Regulatory Factor in Tumor Growth. Nat Rev Cancer. 2002;2(1):38-47.
Northington FJ, Ferriero DM, Graham EM, Traystman RJ, Martin LJ. Early Neurodegeneration after Hypoxia-Ischemia in Neonatal Rat Is Necrosis while Delayed Neuronal Death Is Apoptosis. Neurobiol Dis. 2001;8(2):207-19.
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-39.
Park S-Y, Billiar TR, Seol D-W. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun. 2002;291(1):150-3.
Jeong J-K, Moon M-H, Seo J-S, Seol J-W, Park S-Y, Lee Y-J. Hypoxia inducing factor-1α regulates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in tumor cells exposed to hypoxia. Biochem Biophys Res Commun. 2010;399(3):379-83.
Jeong J-K, Moon M-H, Seo J-S, Seol J-W, Lee Y-J, Park S-Y. Sulforaphane blocks hypoxia-mediated resistance to TRAIL-induced tumor cell death. Mol Med Rep. 2011;4(2):325-30.
Knoll G, Bittner S, Kurz M, Jantsch J, Ehrenschwender M. Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy. Oncotarget. 2016;7(27):41488-504.
Yagci T, Coşkun Y. The tunnel structure of blind mole rats (genus Spalax) in Turkey. Zool Middle East. 2004;50(1):35-40.
Schülke S, Dreidax D, Malik A, Burmester T, Nevo E, Band M, Avivi A, Hankeln T. Living with stress: regulation of antioxidant defense genes in the subterranean, hypoxia-tolerant mole rat, Spalax. Gene. 2012;500(2):199-206.
Avivi A, Shams I, Manov I. Spalax fibroblast-derived anti-cancer agents. Google Patents; 2018.
Schmidt H, Malik A, Bicker A, Poetzsch G, Avivi A, Shams I, et al. Hypoxia tolerance, longevity and cancer-resistance in the mole rat Spalax-a liver transcriptomics approach. Sci Rep. 2017;7(1):1-13.
Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G, Joel A, Amariglio N, Nevo E, Rechavi G. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci. 2004;101(33):12236-41.
Gorbunova V, Hine C, Tian X, Ablaeva J, Gudkov AV, Nevo E, Seluanov A. Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci. 2012;109(47):19392-6.
Ellis M, Stern O, Ashur-Fabian O. The double benefit of Spalax p53: surviving underground hypoxia while defying lung cancer cells in vitro via autophagy and caspase-dependent cell death. Oncotarget. 2016;7(39):63242-51.
Wang Z, Chen Y, Yang J, Chen W, Zhang Y, Zhao X. cDNA cloning and expression of erythropoietin in the plateau zokor (Myospalax baileyi) from the Qinghai-Tibet Plateau. Chin Sci Bull. 2012;57(9):997-1006.
Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012;28(12):1647-9.
Benson G. Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acids Res. 1999;27(2):573-80.
Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS. ONC201 exerts p53-independent cytotoxicity through TRAIL and DR5 induction in mantle cell lymphomas. Blood. 2013;122(21):3822.
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res. 2017;23(15):4163-9.
Anderson PM, Zahler S. Phase II study of ONC201 in pheochromocytoma-paragangliomas (PC-PG), medullary thyroid carcinoma (MTC), and other neuroendocrine tumors. J Clin Oncol. 2020;38(15_suppl):e16703.
Kurz SC, Tarapore R, Odia Y, Butowski NA, Koschmann CJ, Aguilera D, MacDonald TJ, Lu G, Allen JE, Oster W. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. J Clin. Oncol. 2020;38(15_suppl):2563.
Walsh S, Gill C, O’Neill A, Fitzpatrick JM, Watson RWG. Hypoxia increases normal prostate epithelial cell resistance to receptor-mediated apoptosis via AKT activation. Int J Cancer. 2009;124(8):1871-8.
Pei G-T, Wu C-W, Lin W-W. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1α-mediated mechanism. Biochem Biophys Res Commun. 2010;391(2):1274-9.
de Looff M, de Jong S, Kruyt FAE. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. Front Immunol. 2019;10:1530.
Paneerselvam C, Ganapasam S. β-Escin alleviates cobalt chloride-induced hypoxia-mediated apoptotic resistance and invasion via ROS-dependent HIF-1α/TGF-β/MMPs in A549 cells. Toxicol Res. 2020;9(3):191-201.
Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388(6639):300-4.
Dumétier B, Zadoroznyj A, Dubrez L. IAP-Mediated Protein Ubiquitination in Regulating Cell Signaling. Cells. 2020;9(5):1118.
Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 2009;35(3):280-8.
Lu J, Qin Q, Zhan LL, Liu J, Zhu HC, Yang X, Zhang C, Xu LP, Liu ZM, Wang D, Cui HQ, Meng CC, Cai J, Cheng HY, Sun XC. AT-406, an IAP inhibitor, activates apoptosis and induces radiosensitization of normoxic and hypoxic cervical cancer cells. J Pharmacol Sci. 2014;126(1):56-65.
Belluardo N, Korhonen L, Mudo G, Lindholm D. Neuronal expression and regulation of rat inhibitor of apoptosis protein‐2 by kainic acid in the rat brain. Eur J Neurosci. 2002;15(1):87-100.
Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, Semenza GL, Force T, Nishiyama J. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia HIF-1-independent mechanisms. J Biol Chem. 2001;276(22):18702-9.
Alonso J, Galán M, Martí-Pàmies I, Romero JM, Camacho M, Rodríguez C, Martínez-González J. NOR-1/NR4A3 regulates the cellular inhibitor of apoptosis 2 (cIAP2) in vascular cells: role in the survival response to hypoxic stress. Sci Rep. 2016;6:34056.
Harashima N, Takenaga K, Akimoto M, Harada M. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression. Oncotarget. 2017;8(26):42887.
Russell JC, Whiting H, Szuflita N, Hossain MA. Nuclear translocation of X‐linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. J Neurochem. 2008;106(3):1357-70.
Askalan R, Salweski R, Tuor UI, Hutchison J, Hawkins C. X-Linked Inhibitor of Apoptosis Protein Expression After Ischemic Injury in the Human and Rat Developing Brain. Pediatr Res. 2009;65(1):21-6.
Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candidates for cancer therapy. Drug Discov Today. 2010;15(5):210-9.
Wang X, Wang Y, Zhang J, Kim HP, Ryter SW, Choi AM. FLIP protects against hypoxia/reoxygenation-induced endothelial cell apoptosis by inhibiting Bax activation. Mol Cell Biol. 2005;25(11):4742-51.
O’Leary L, van der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SPS, Murillo LS, Cool RH, de Sampaio PC, Thompson K. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene. 2016;35(10):1261-70.
Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol. 2007;177(1):359-64.
Huang Z, Song L, Wang C, Liu J-Q, Chen C. Hypoxia-ischemia upregulates TRAIL and TRAIL receptors in the immature rat brain. Dev Neurosci. 2011;33(6):519-30.
Kichev A, Rousset CI, Baburamani AA, Levison SW, Wood TL, Gressens P, Thornton C, Hagberg H. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation. J Biol Chem. 2014;289(13):9430-9.
Xu W, Jin W, Zhang X, Chen J, Liu M, Zhang S, Ren C. Dcr1 and Dcr2 Protect Neuron Against Ischemia and Hypoxia Damage via Differential Mechanisms on Ischemia Preconditioning-Induced Neuroprotection. Stroke. 2018;49(Suppl_1):AWP261.
Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J Biol Chem. 2005;280(50):41155-64.
Lang I, Füllsack S, Wyzgol A, Fick A, Trebing J, Arana JAC, Schäfer V, Weisenberger D, Wajant H. Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells. J Biol Chem. 2016;291(10):5022-37.
Trevino SR, Scholtz JM, Pace CN. Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa. J Mol Biol. 2007;366(2):449-60.
Qin S, Zhang Q, Zhang L. Effect of OPG gene mutation on protein expression and biological activity in osteoporosis. Exp Ther Med. 2017;14(2):1475-80.
Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia inhibits TRAIL-induced tumor cell apoptosis: involvement of lysosomal cathepsins. Apoptosis. 2007;12(1):125-39.
Lee YJ, Moon M-S, Kwon SJ, Rhee JG. Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death. Mol Cell Biochem. 2005;270(1‑2):89-97.
Boyle AL, Woolfson DN. De novo designed peptides for biological applications. Chem Soc Rev. 2011;40(8):4295-306.
Weckmann M, Kopp MV, Heinzmann A, Mattes J. Haplotypes covering the TNFSF10 gene are associated with bronchial asthma. Pediatr Allergy Immunol. 2011;22(1):25-30.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Archives of Biological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
